Skip to content

A randomized, double blind, multi-center, active drug controlled,phase III clinical trial to compare the safety and efficacy of BOTULAX® versus BOTOX® in treatment of post stroke upper limb spasticity.

A randomized, double blind, multi-center, active drug controlled,phase III clinical trial to compare the safety and efficacy of BOTULAX® versus BOTOX® in treatment of post stroke upper limb spasticity.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0001188
Enrollment
186
Registered
2014-08-04
Start date
2013-08-26
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine, Non-Stem Cell : At baseline, Botulax or Botox is injected intramuscularly in the target muscle/s at a maximum dose of 360U

Sponsors

Hugel
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female subjects no younger than 20 years of age. 2. Patients diagnosed with stroke =6 weeks prior to enrollment in current study 3. Focal spasticity score = 2 points at wrist flexor and = 1 point at one or more of the following muscles: elbow flexor and/or finger flexor (scores measured on the MAS (0 to 4)) 4. A minimum of grade 2 in the targeted functional disability item (i.e., hygiene, dressing, upper-limb position sense, or pain) on the Disability Assessment Scale (0 to 3) 5. Voluntary informed consent signed by patient or patient’s legal guardian after objective, methods, and efficacy of clinical study have been explained

Exclusion criteria

Exclusion criteria: 1. Subjects who have a history of Neuromuscular Junction Disorders (Ex,Myasthenia Graris,Lambert-Eaton myasthenic syndrome, Congenital myasthenic syndrome) 2. Patients with significant atrophy of the muscle in the target limb 3. Patients with fixed joint/muscle contracture* in the target limb * Defined as inability to passively move the joints 4. Prior (within 6 months of administration of study drug) or planned (during study period) treatment with phenol/alcohol injection (chemodenervation) in the target limb 5. Prior (within 6 months of administration of study drug) or planned (during study period) tendon lengthening surgery in the target limb

Design outcomes

Primary

MeasureTime frame
Improvement of Modified Ashworth Scale (MAS) scores of wrist flexor evaluated by the investigator in weeks 4 from the Investigatioal Product injection

Secondary

MeasureTime frame
Improvement of Modified Ashworth Scale (MAS) scores of elbow flexor, finger flexor, thumb flexor evaluated by the investigator in weeks 4 from the Investigatioal Product injection;Improvement of Modified Ashworth Scale (MAS) scores of wrist flexor, elbow flexor, finger flexor, thumb flexor evaluated by the investigator in weeks 8,12 from the Investigatioal Product injection;Laboratory Tests;Vital Signs (Blood pressure, pulse and temperature)

Countries

Korea, Republic of

Contacts

Public ContactHyunju Shin

Hugel

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026